Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado. Show more

6200 Lookout Road, Boulder, CO, 80301, United States

Start AI Chat

Market Cap

1.629B

52 Wk Range

$13.30 - $30.22

Previous Close

$27.45

Open

$27.68

Volume

871,344

Day Range

$27.62 - $28.92

Enterprise Value

690M

Cash

477.6M

Avg Qtr Burn

-13.28M

Insider Ownership

8.27%

Institutional Own.

-

Qtr Updated

09/30/25